Authors
Natali Pflug, Sandra Kluth, Jörg J Vehreschild, Jasmin Bahlo, Daniela Tacke, Lena Biehl, Barbara Eichhorst, Kirsten Fischer, Paula Cramer, Anna-Maria Fink, Michael von Bergwelt-Baildon, Stephan Stilgenbauer, Michael Hallek, Oliver A Cornely, Maria JGT Vehreschild
Publication date
2016/6/2
Journal
Oncoimmunology
Volume
5
Issue
6
Pages
e1150399
Publisher
Taylor & Francis
Description
Reduced anticancer efficacy of cyclophosphamide and platinum salts has been reported in animals treated with anti-Gram-positive antibiotics. These effects were related to translocation of Gram-positive bacteria during mucositis with subsequent induction of cytotoxic oxygen reactive species and tumor invasion by pathogenic Th17 cells. To assess these hypotheses in a clinical setting, we identified patients receiving cyclophosphamide for chronic lymphocytic leukemia (CLL) and cisplatin for relapsed lymphoma. Data originated from the CLL8 trial (NCT00281918) and the Cologne Cohort of Neutropenic Patients (NCT01821456). Relevant antibiotics were defined as compounds with primary activity against Gram-positive bacteria. We evaluated their impact on response, progression-free survival (PFS) and overall survival (OS) by Kaplan–Meier methodology and Cox proportional hazards regression analysis. Among …
Total citations
201720182019202020212022202320247513182218226